Hospital
Davie Medical Center, LLC
Davie Medical Center, LLC was paid $2.56M by Medicaid between Nov 2021 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 39% of everything it billed.
33Billing provider infoDAVIE MEDICAL CENTER, LLC
DAVIE, FL 33328
DAVIE, FL 33328
33aNPI1871182956assigned 01/13/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.56M
24GClaims97,122
24DCodes billed100
24AFirst – last monthNov 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#109 of 163
Median peer was paid$4.77M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 3,948 | $87K | |
| 2022 | 44,287 | $1.08M | |
| 2023 | 33,869 | $924K | |
| 2024incomplete | 15,018 | $466K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 39% | 8,716 | 7,457 | $987K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 8,032 | 7,311 | $883K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.9% | 499 | 431 | $126K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.9% | 855 | 747 | $100K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 276 | 244 | $93K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 740 | 654 | $86K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 192 | 172 | $58K |
| G0378 | Hospital observation service, per hour | 2.3% | 1,331 | 666 | $58K |
| 80053 | Comprehensive metabolic panel | 1.4% | 6,802 | 5,736 | $36K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 697 | 309 | $32K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 731 | 619 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,746 | 4,437 | $10K |
88 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,250 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 669 | $5K |
| 87040 | <1% | 419 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,254 | $5K |
| 87807 | <1% | 937 | $4K | |
| 87070 | <1% | 1,703 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,454 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 180 | $3K |
| 87275 | <1% | 4,389 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,310 | $3K |
| 76801 | <1% | 423 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 341 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 209 | $2K |
| 85027 | <1% | 8,136 | $2K | |
| 81025 | <1% | 1,372 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 280 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,143 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 169 | $2K |
| 87276 | <1% | 4,389 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 647 | $2K |
| 74022 | <1% | 37 | $1K | |
| 72131 | <1% | 13 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,682 | $1K |
| 87480 | <1% | 157 | $640.93 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 306 | $498.62 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,809 | $378.06 |
| 81001 | <1% | 3,000 | $363.96 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,142 | $332.36 |
| 72100 | <1% | 15 | $210.72 | |
| 83690 | <1% | 1,491 | $208.68 | |
| 85610 | <1% | 711 | $181.03 | |
| 85730 | <1% | 675 | $181.03 | |
| 76830 | Ultrasound, transvaginal | <1% | 34 | $142.10 |
| 87077 | <1% | 196 | $131.04 | |
| 84703 | <1% | 1,770 | $126.76 | |
| 84484 | <1% | 1,166 | $122.43 | |
| A9270 | Non-covered item or service | <1% | 133 | $93.79 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 392 | $72.62 |
| 81003 | <1% | 1,168 | $60.75 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 217 | $40.12 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 160 | $39.91 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 666 | $21.08 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 779 | $20.77 |
| 84702 | <1% | 583 | $17.50 | |
| 86140 | <1% | 234 | $14.40 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 135 | $5.10 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 380 | $3.33 |
| 86900 | <1% | 750 | $2.50 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 559 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 376 | $0.00 |
| 99238 | Hospital discharge day management, 30 minutes or less | 0% | 69 | $0.00 |
| 85007 | 0% | 262 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 275 | $0.00 |
| 74018 | 0% | 71 | $0.00 | |
| 87660 | 0% | 157 | $0.00 | |
| 73562 | 0% | 29 | $0.00 | |
| 73630 | 0% | 40 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 27 | $0.00 |
| 73610 | 0% | 14 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 21 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 16 | $0.00 |
| 80076 | 0% | 13 | $0.00 | |
| 86850 | 0% | 454 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 356 | $0.00 |
| 86901 | 0% | 454 | $0.00 | |
| 83605 | 0% | 344 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 415 | $0.00 |
| 83735 | 0% | 68 | $0.00 | |
| 87487 | 0% | 159 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 44 | $0.00 |
| 82550 | 0% | 79 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 394 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 159 | $0.00 |
| 99460 | 0% | 56 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 92 | $0.00 |
| 92650 | 0% | 1,210 | $0.00 | |
| 83880 | 0% | 108 | $0.00 | |
| 85379 | 0% | 130 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 27 | $0.00 |
| 87510 | 0% | 157 | $0.00 | |
| 85651 | 0% | 51 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 148 | $0.00 |
| J3490 | Unclassified drugs | 0% | 76 | $0.00 |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 0% | 19 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 55 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 15 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISCHESSER, DANIEL (CFO)